Vasopressin antagonist drugs?

Vasopressin receptor antagonists (aka vaptans) are drugs that block the action of vasopressin (antidiuretic hormone) in the kidney, promoting free water excretion (aquaresis) and helping raise low sodium levels in hyponatremia. They are used mainly for euvolemic or hypervolemic hyponatremia (often due to SIADH or heart failure), and some have other approved uses in specific regions.

Commonly used vaptans
- Tolvaptan (Samsca)
- Mechanism: selective V2 receptor antagonist (kidney). Oral.
- Indications: hyponatremia due to SIADH and other causes of euvolemic/hypervolemic hyponatremia; in some places also approved to slow cyst growth in autosomal dominant polycystic kidney disease (ADPKD).
- Notes: risk of hepatotoxicity with long-term use; monitor liver function and sodium; avoid in hypovolemic states; interactions with CYP3A4 inhibitors/inducers.

- Conivaptan (Vaprisol)
- Mechanism: dual V1A and V2 receptor antagonist (primarily V2 in the kidney, but also blocks V1A effects).
- Indications: hospitalized patients with euvolemic or hypervolemic hyponatremia.
- Notes: IV only; may cause infusion-related reactions and electrolyte shifts; also interacts with CYP3A4 inhibitors/inducers.

Other agents and notes
- Demeclocycline
- Not a direct vasopressin receptor antagonist, but historically used off-label to treat SIADH by causing nephrogenic diabetes insipidus (reduces responsiveness to vasopressin). Not first-line due to nephrotoxicity and other side effects.

- Other vasopressin receptor antagonists (investigational or region-specific)
- Lixivaptan, Mozavaptan, Satavaptan, and others have been studied in various countries but are not broadly approved in the United States. Some have been in development for hyponatremia; availability varies by country and approval status.
- Relcovaptan (a V1A antagonist) has been studied for vasodilatory indications (e.g., Raynaud’s phenomenon) but is not used for hyponatremia.

Key safety and monitoring points
- Hyponatremia correction: risk of overly rapid correction leading to osmotic demyelination; sodium should be monitored regularly after starting therapy.
- Liver safety: tolvaptan has a notable risk of liver injury with long-term use; monitor liver function tests.
- Volume status: these drugs alter water balance; assess for hypovolemia or dehydration.
- Drug interactions: many vaptans are processed by CYP enzymes (e.g., CYP3A4); check for interactions with other medications.
- Contraindications: may include hypovolemia, anuria, significant hepatic impairment (for some agents), and other drug-specific restrictions.

If you’d like, tell me your country or the specific context (e.g., SIADH-related hyponatremia, heart failure, SIADH with liver precautions), and I can tailor a more precise list of approved options and monitoring guidelines.